

[^{18}O]dAMP, the ^{18}O perturbation in the Δ complex is 2.5 Hz and that in the Λ complex is 1.3 Hz; these relative values demonstrate that the absolute configuration of this sample of uncomplexed [α - ^{18}O]dADP is *R_p*. These assignments are in agreement with those predicted on the basis of the configurations of the precursor cyclic [^{18}O]dAMP samples and the stereochemical course of the adenylate cyclase reaction determined by using ATP α S as substrate. Thus, the stereochemical course of the reaction catalyzed by this enzyme is inversion of configuration by using either oxygen chiral or phosphorothioate substrates.

These results illustrate the considerable utility of substitution-inert Co(III) complexes in determining the configuration at the α -phosphorus atom of oxygen chiral [α - ^{18}O]nucleoside diphosphates. Since substitution-inert β,γ -bidentate complexes of nucleoside triphosphates can be prepared²⁹ and their screw senses have been assigned,³⁶ examination of the ^{18}O perturbations of the β -phosphorus atoms in complexes prepared from oxygen chiral [β - ^{18}O] nucleoside triphosphates should be the most convenient method for determining their configurations.

The enzymatic syntheses of the diastereomers of [α - ^{18}O]ADP are currently in progress.

Acknowledgment. We are grateful to Professor W. W. Cleland for helpful discussions and to Peter Demou, Michael Fuson, and Professor Ian M. Armitage for their assistance in obtaining the high-field ^{31}P NMR spectra. This research was supported by a grant (GM-22350) from the National Institutes of Health. The high-field NMR spectrometer used in this research (Bruker CXP-200) is supported by a grant from the National Science Foundation (CHE-7916120).

(36) Merritt, E. A.; Sundaralingam, M.; Cornelius, R. D.; Cleland, W. W. *Biochemistry* 1978, 17, 3274.

(37) NIH Research Career Development Awardee (CA-00499), 1978-1983.

Jeffrey A. Coderre, John A. Gerlt*³⁷

Department of Chemistry, Yale University
New Haven, Connecticut 06511

Received June 23, 1980

Total Synthesis of (\pm)-Maytansinol. The Common Precursor to the Maytansinoids

Sir:

The ansa macrocyclic antitumor substances, maytansinoids, originally isolated and characterized by Kupchan,¹ have been the focus of many pharmacological² and synthetic efforts.³ These highly potent materials are currently undergoing clinical trials under the auspices of the National Cancer Institute. In the last 2 years, there have been successful routes reported for (\pm)-*N*-methylmaysenine (2) in racemic⁴ and optically active⁵ forms and (\pm)-maysine 3,⁶ the first naturally occurring maytansinoid. We report herein the total synthesis of (\pm)-maytansinol 1a which

(1) Kupchan, S. M.; Komodo, Y.; Branfman, A. R.; Sneden, A. T.; Court, W. A.; Thomas, G. J.; Hintz, H. P. J.; Smith, R. M.; Karim, A.; Howie, G. A.; Verma, A. K.; Nagao, Y.; Dailey, R. G.; Zimmerly, V. A.; Sumner, W. C. *J. Org. Chem.* 1977, 42, 2349.


(2) Chabner, B. A.; Levine, A. S.; Johnson, B. L.; Young, R. C. *Cancer Treat. Rep.* 1978, 62, 429.

(3) (a) Gotschi, E.; Schneider, F.; Wagner, H.; Bernauer, K. *Helv. Chim. Acta* 1977, 60, 1416. (b) Samson, M.; DeClerq, P.; DeWilde, H.; Vandewalle, M. *Tetrahedron Lett.* 1977, 3195. (c) Edwards, O. E.; Ho, P.-T. *Can. J. Chem.* 1977, 55, 371. (d) Elliot, W. J.; Fried, J. *J. Org. Chem.* 1976, 41, 2469. (e) Bonjouklian, R.; Ganem, B. *Tetrahedron Lett.* 1977, 2835.


(4) Corey, E. J.; Weigel, L. O.; Floyd, D.; Bock, M. G. *J. Am. Chem. Soc.* 1978, 100, 2916. Meyers, A. I.; Roland, D. M.; Comins, D. L.; Henning, R.; Fleming, M. P.; Shimizu, K. *Ibid.* 1979, 101, 4732.

(5) Corey, E. J.; Weigel, L. O.; Chamberlin, A. R.; Lipshutz, B. *J. Am. Chem. Soc.* 1980, 102, 1439.


(6) Meyers, A. I.; Comins, D. L.; Roland, D. M.; Henning, R.; Shimizu, K. *J. Am. Chem. Soc.* 1979, 101, 7104.



1a, R = H
1b, R = COCH(CH₃)N(CH₃)COCH₃
1c, R = COCH₃




N-methylmaysenine (2)




maysine (3)

contains all the requisite functionality and stereochemical properties of the antitumor agents maytansine (1b), maytanacine (1c), and other simple acylated derivatives.⁷ Since natural (-)-1a has been transformed via routine acylation to (-)-1b, (-)-1c, and other esters at C-3, this also constitutes the formal total synthesis, in racemic form, for these highly active tumor inhibitors and establishes 1a as the pivotal precursor to all these interesting substances.

The synthetic scheme leading to (\pm)-1a follows from the key intermediate 4a⁸ which served as the precursor to (\pm)-maysine.⁶



4a, R₁ = H, R₂ = CHO
4b, R₁ = COCH₃, R₂ = CHO
4c, R₁ = COCH₃, R₂ = CO₂Me



5

(7) Maytansinol is the key precursor isolated by Kupchan¹ and observed by the Takeda Company group and transformed into a variety of acylated derivatives at C-3: Higashida, E.; Asai, M.; Ootsu, K.; Tanida, S.; Kozai, Y.; Hasegawa, T.; Kishi, T.; Sugino, Y.; Yoneda, M. *Nature (London)* 1977, 270, 721.

Table I. ¹H NMR Data for Synthetic and Natural Maytansinol

proton(s)	synthetic (±)-1a	authentic (-)-1a	authentic (from ref 1) (-)-1a at 100 MHz
C-4 Me (s)	0.82	0.82	0.84
C-6 Me (d)	1.30	1.32	1.32
	(<i>J</i> = 6.5 Hz)	(<i>J</i> = 6.5 Hz)	(<i>J</i> = 6 Hz)
C-14 Me (s)	1.70	1.70	1.68
C-2 H (a portion, AB q)	2.54	2.54	
	(<i>J</i> = 9.7 Hz)	(<i>J</i> = 9.7 Hz)	
N-Me (s)	3.20	3.20	3.20
C-10 OMe (s)	3.35	3.35	3.36
C-9 OH (br s)	3.60	3.60	3.64
Ar-OMe (s)	3.98	3.98	3.98
C-7 H (m)	4.28–4.35	4.29–4.35	4.36
C-11 H (d of d)	5.50	5.50	5.53
	(<i>J</i> = 9, 15 Hz)	(<i>J</i> = 9, 15 Hz)	(<i>J</i> = 9, 15 Hz)
C-13 H (m)	6.13, 6.16	6.13, 6.16	6.19–6.39
C-13 H (m)	6.22, 6.40, 6.43, 6.44	6.22, 6.40, 6.43, 6.44	
NH (m)	6.47	6.47	
ArH	6.81, 6.91	6.81, 6.91	6.81, 7.05
unassigned m	3.10–3.49, 2.11–2.29	3.10–3.49, 2.10–2.29	

Acetylation (CH₃COCl, pyridine, 0 °C, 3 h) of the secondary amine gave the N-acetyl compound **4b**⁹ in 97% yield, and the aldehyde was oxidized (10 equiv of AgNO₃, 20 equiv of NaOH, THF–H₂O, 25 °C, 2 h) to the acid and immediately treated with diazomethane–ether at 0 °C to give the methyl ester **4c** in 65% yield.¹⁰ The cyclization to **5** was accomplished in 58% yield by using 4 equiv of lithium (hexamethylsilyl)amide (–78 °C, THF, 5 × 10^{–3} M, 4 h) and once again showed that anionic ring closures in large rings were indeed a feasible process.^{6,11} The next event to be accomplished was the proper removal of the protecting groups at C-7 and C-9. It was necessary to first remove the ethyl thioketal to **6**¹² [2.2 equiv of HgCl₂, 2.6 equiv of CaCO₃, CH₃CN–H₂O (4:1), 25 °C, 1.5 h] which proceeded in 98% yield, followed by hydrolytic removal of the ethoxyethyl group (1.0 N HCl, THF, 0 °C, 2 h) to **7**.¹³ If the ethoxyethyl group was removed prior to the thioketal, extensive decomposition of the molecule resulted, presumably due to the acidic lability of the allylic methyl ether at C-10. Introduction of the cyclic carbinolamide was performed by treating the β-hydroxy ketone **7** with 8.0 equiv of phenyl chloroformate and 8.0 equiv of pyridine in ether–THF (1:1) at 0 °C for 1 h. This gave **8**¹⁴ which was immediately added to excess

(8) Compound **4a** was formed in the previous study⁶ as a 1:1 mixture of epimers at C-10 and an undetermined epimeric mixture of ethoxy ethyl ethers at C-7. The latter was removed at a later stage, whereas the C-10 epimers were ultimately separated in the final isolation of **1a**.


(9) High-pressure LC analysis (Waters 244; μ-porasil, 30 cm) in 20% THF–hexane at a flow rate of 3 mL/min gave two peaks, 4.8 and 5.2 min (1:1), shown to be epimers at C-10. The epimeric centers at C-7 were shown in an independent experiment not to interfere with the analysis at C-10. Physical data for **4b**: IR (film) 2710, 1725, 1662 cm^{–1}; ¹H NMR (CDCl₃) δ 1.50, 1.52 (3, 2 s, C-4 Me due to epimers at C-10), 1.74 (3 s, C-14 Me), 1.81 (3 s, N–Ac), 3.20 (3 s, N–Me), 3.26 (3 s, C-10 OMe), 3.38 (2, br s, C-15 H), 3.95 (3 s, Ar–OMe), 6.77 (2, br s, ArH), 8.84, 8.87 (1, s, CHO due to epimers at C-10).

(10) **4c**: IR (film) 1737, 1666 cm^{–1}; ¹H NMR (CDCl₃) δ 1.58, 1.60 (3 s, C-4 Me, as a 1:1 mixture of epimers at C-10), 3.71 (3 s, CO₂Me). High-pressure LC analysis (μ-porasil, 30% THF–hexane, 2 mL/min) showed 4.4 and 4.7 min for epimers at C-10. Purification by PTLC (20% acetone–hexane) gave purified material as a 1:1 mixture of C-10 epimers, *R_f* 0.2.

(11) **5**: IR (CHCl₃) 1718, 1655 cm^{–1}; UV (MeOH) λ_{max} 344, 328, 289, 280, 255, 235 nm; ¹H NMR (CDCl₃) δ 3.20 (3 s, N–Me), 3.22 (3 s, C-10 OMe), 3.90 and 3.92 (ArOCH₃ as a 1:1 epimeric mixture due to C-10); ¹³C NMR (CDCl₃) 203.4, 203.6 (C-3 carbonyl). High-pressure LC (μ-porasil, 30% THF–hexane, 2 mL/min) gave a peak at 2.8 min; purification by PTLC, same solvent, gave *R_f* 0.28.

(12) **6**: IR (CH₂Cl₂) 1710, 1648 cm^{–1}; ¹H NMR (CDCl₃) δ 3.21 (3 s, N–Me), 3.40 (3 s, C-10 OMe), 3.94 (3 s, ArOMe), 4.53–4.92 [m, –CH–(Et)(OEt)]. Purification by PTLC (30% acetone–hexane) gave *R_f* 0.11.

(13) **7**: IR (film) 3415, 1716, 1652 cm^{–1}; ¹H NMR (CDCl₃) δ 3.15, 3.18 (3 s, N–Me as a 1:1 mixture of epimers from C-10), 3.38 (3 s, C-10 OMe), 3.94 (3 s, ArOMe).



ammonia dissolved in THF at –78 °C and allowed to stir overnight, furnishing **9**¹⁵ in ~50–55% yield.

The remaining step to be carried out required reduction of the C-3 carbonyl in **9**, and this was performed by using sodium borohydride [THF–MeOH (1:1), –40 °C, 30 min] and gave, in 94% yield, an epimeric mixture of four compounds, the major product (~45%) being isolated with the aid of high-pressure liquid chromatography (high-pressure LC). Comparison of this product with authentic natural (–)-maytansinol¹⁶ was rather gratifying, indicating total identity with high-pressure LC (μ-porasil, 30 cm, 5% MeOH–CHCl₃, 4.5 min), PTLC (silica gel, 7% MeOH–CHCl₃, *R_f* 0.15), mass spectroscopy, UV, and ¹H NMR spectra (Table I).¹⁷

The completion of this synthetic goal leading to (±)-maytansinol now allows us to pursue the asymmetric synthesis¹⁸ of natural and unnatural derivatives as well as suitable analogues for biological assay. This work is currently in progress.

Acknowledgment. We express our gratitude to the Colorado State University Regional NMR Center funded by the National Science Foundation (CHE 78-18581) for the 360-MHz spectral data, Dr. Phillip Ryan for the mass spectral data, and the National Cancer Institute (R01 CA16051) for generous financial support of this program over the last 7 years. National Service Research Awards (to P.J.R. and A.L.C.) for 1978–1980 are also gratefully acknowledged. We also thank Dr. James Hudspeth for technical assistance.

(14) **8** was not isolated except for a sample to assess the extent of the carbonate formation: IR (CH₂Cl₂) 1755 (carbonate), 1713, 1650 cm^{–1}.

(15) **9**: IR (CH₂Cl₂) 3100–3500 (NH, OH), 1710, 1651, 1635 (carbinolamide) cm^{–1}. High-pressure LC analysis (μ-porasil, 30 cm; 5% MeOH–CHCl₃, 2 mL/min) gave a peak at 2.3 min.

(16) We are grateful to Dr. T. Kishi of the Takeda Company, Osaka, for providing us with authentic (–)-maytansinol for comparison.

(17) Physical data comparison of synthetic and natural maytansinol. (a) Ultraviolet spectrum (MeOH, nm): natural (–)-**1a** 232, 244, 252, 281, 288 (cf. ref 1); synthetic (±)-**1a** 233, 243, 252, 281, 288. (b) Mass spectrum (70 eV): natural (–)-**1a** 503 (26), 485 (32), 468 (29), 453 (19), 450 (22), 374 (15), 294 (43), 236 (100), 224 (62); synthetic (±)-**1a** 503 (31), 485 (100), 468 (63), 453 (44), 450 (22), 374 (42), 294 (25), 236 (77), 224 (48). (c) Proton magnetic resonance spectrum (360 MHz, CDCl₃, δ): see Table I.

(18) The C-3 to C-7 fragment of the molecule has been prepared via asymmetric synthesis to enantiomerically pure material. This work will be reported in due course.

A. I. Meyers,* Paul J. Reider, Arthur L. Campbell
Department of Chemistry, Colorado State University
Fort Collins, Colorado 80523

Received June 9, 1980